Joining global efforts to fight SARS-CoV-2, Biortus is offering several products and services to both scientific and industrial communities to assist researchers in finding effective treatments against the virus.
Using its well-established protein production platform, Biortus offers a number of high purity nonstructural proteins (NSPs) of SARS-CoV-2, including NSP12 (a.k.a. RNA-dependent RNA polymerase, RdRp, one of the most critical drug target), and NSP5 (3CL Pro, SARS-CoV-2’s main protease). Shown below are the SDS-PAGE results of the NSPs from Biortus indicating their high purity suitable for research purposes. Biortus also offers custom productions of the NSP complexes with each other, other proteins/peptides, and small molecules. Biortus has also produced SARS-CoV-2’s S protein and its related receptor ACE2.
Biortus is also specialized in structural biology. For the critical drug target protein NSP5, Biortus has reproduced its crystal. One of our routine services is to screen small molecules via co-crystallization or soaking and then to obtain their complex structures. We welcome researchers to contact us for this service as well as for crystallographic studies of these proteins.
If your protein is non-crystalline, e.g., the RNA-dependent RNA polymerase NSP12, Biortus can cover that as well. Our experienced cryoEM team will obtain the 3-D structure of non-crystalline proteins and complexes for you. This process is conveniently facilitated with our in-house TF20 electron microscope and guaranteed access to multiple high-end Krios.
Furthermore, Biortus bio-analytics team develops and conducts in vitro assays to help our clients assess biological activities. With our in-house setups, such as Biacore SPR (e.g. ACE2/spike protein interaction), ThermoFluor assay (e.g. screening inhibitors with Tm shift), Plate reader assay (e.g. UV-Vis, FA, FP, HTRF) and Fluorescent gel shift assay, Biortus team routinely evaluates biochemical, biophysical, and cell-based properties for a variety of pathogens including the SARS-CoV-2 virus. One of our work is demonstrated in a recent Science article (https://science.sciencemag.org/content/early/2020/04/30/science.abc1560
“From Gene to Structure”, Biortus, the protein-focused CRO company, is ready to support your drug discovery.